Prostate Cancer Discoveries Digest: October 2024
ZERO Prostate Cancer
We're on a mission to ZERO Out prostate cancer. #ZEROProstateCancer
Welcome to the October edition of ZERO’s Prostate Cancer Discoveries Digest! The latest information on treatment, diagnostics, outcomes, and more has been pulled from the headlines and delivered straight to your inbox.
ZERO Prostate Cancer does not endorse any particular article or finding that may be featured.
Health Equity
The physical, economic, and social conditions of neighborhoods have long been recognized as significant factors associated with cancer outcomes in racially and ethnically diverse populations, and researchers aimed to understand better how neighborhood deprivation affects prostate cancer outcomes.
Treatment
Researchers at Duke University help uncover how bi-polar androgen therapy, or BAT, works and which patients are likely to respond to this type of treatment.
Outcomes
In a study of nearly 60,000 prostate cancer patients, researchers reviewed trends in overall survival (OS) by location of metastatic disease - bone, lung, liver, and brain - and by race.
Diagnostics
Researchers find the diagnostic accuracy of MRI for finding clinically significant prostate cancer recurrence after partial gland ablation with HIFU to be challenging.
Recommended by LinkedIn
Treatment
Two new targets, NSD1 and NSD2, have been identified as viable targets in the treatment of advanced prostate cancer and could, in the future, be combined with FDA-approved androgen receptor antagonists.
Diagnostics
More than 850 people with suspected prostate cancer were randomized, with half undergoing transperineal prostate biopsy and half undergoing transrectal biopsy being studied for infection, the detection of high-grade cancer, and other complications.
Diagnostics
In this study, whole-body MRI was compared to CT and bone scans in newly diagnosed patients with high-risk prostate cancer.
Genetics & Genomics
A study published in JAMA Oncology revealed that only 37% of metastatic prostate cancer patients underwent genetic testing despite national guidelines that recommend it for these patients.
ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to take the place of medical professionals or the recommendations of your healthcare team. Consult your healthcare team if you have questions about your specific treatment plan.
Join our mailing list to get the latest in prostate cancer news, events, advocacy, and community!
© 2024 ZERO Prostate Cancer. All rights reserved. ZERO is a 501(c)(3) non-profit organization.